Core Viewpoint - The article discusses the recent approval of clinical trials for Semaglutide injection by Taiji Group's subsidiary, indicating a significant step in the GLP-1 drug market in China, which is currently dominated by Novo Nordisk's product. Group 1: Clinical Trial Approval - Taiji Group's subsidiary, Fuling Pharmaceutical Factory, has received the clinical trial approval notice from the National Medical Products Administration for Semaglutide injection [2] - The clinical trial is aimed at adult patients with type 2 diabetes who have not achieved blood sugar control despite using metformin and/or sulfonylureas, as well as those with cardiovascular diseases [6] Group 2: Market Competition - As of the announcement date, Novo Nordisk is the only company with an approved Semaglutide injection in China, generating significant revenue of $29.296 billion in 2024 [7] - Taiji Group's entry into the GLP-1 market signifies the emergence of new competition, with the company claiming advantages in quality and large-scale production through efficient yeast expression technology [7] Group 3: Research and Development Investment - The cumulative R&D investment for the Semaglutide project by Taiji Group is approximately RMB 44.1834 million (unaudited) [8] - Following the approval, Fuling Pharmaceutical Factory will initiate clinical trials and submit data to the regulatory authority for production and market approval [8] Group 4: Company Overview - Taiji Group is a large pharmaceutical manufacturing enterprise in China, involved in traditional Chinese medicine, chemical drugs, and active pharmaceutical ingredients [9] - The company's move into the GLP-1 target is viewed as a crucial step towards its transformation into modern biopharmaceuticals [9]

Group 1 - Junshi Bioscience's product Mindewei achieved full-channel coverage in the first half of 2025, exploring community and county market medical cooperation models [1] - Mindewei was conditionally approved for marketing by the National Medical Products Administration in January 2023, and the company has actively built a commercialization team [1] - The company has established strategic partnerships with national pharmaceutical companies and chain pharmacies, and is exploring sales models on platforms like Meituan, JD, and Alibaba Health [1] Group 2 - Changchun High-tech's subsidiary GS3-007a dry mixed suspension has received acceptance for its clinical trial application, aimed at treating pediatric growth hormone deficiency (PGHD) [2] - PGHD is a common endocrine disease in pediatrics, with an incidence rate of approximately 1 in 8600 in China, primarily caused by insufficient secretion of growth hormone-releasing hormone [2] Group 3 - Chengda Biologics has gained market access for its human rabies vaccine in Indonesia and is actively expanding into larger markets like Brazil [3] - The company's international business has shown significant growth, covering over 30 countries, and is advancing its "vaccine going abroad" strategy [3] Group 4 - Taiji Group's subsidiary has received clinical trial approval for semaglutide injection, targeting blood sugar control in adults with type 2 diabetes [4] - The indication includes patients whose blood sugar remains uncontrolled despite diet and exercise, and those at risk of major cardiovascular events [4] Group 5 - China National Pharmaceutical Group plans to strengthen accounts receivable management and establish a tracking ledger for key customers [5] - The company reported a net cash flow of -546 million yuan in the first half of 2025, a significant improvement from -743 million yuan in the same period last year [5] Group 6 - Zhend Medical expects its African production base to break even by the end of the year while actively advancing the construction of its Mexican production base [6][7] - The company is focusing on expanding into emerging markets with increasing demand for basic medical supplies and is enhancing operational efficiency in its African base [6][7]

Core Viewpoint - Taiji Group's subsidiary has received clinical trial approval for Semaglutide injection, a GLP-1 receptor agonist for type 2 diabetes management and weight control [1][2]. Group 1: Company Developments - Taiji Group's subsidiary, Chongqing Fuling Pharmaceutical Factory, has obtained the clinical trial approval notice from the National Medical Products Administration for Semaglutide injection [1]. - The approved indication for the clinical trial is for blood sugar control in adult patients with type 2 diabetes who have inadequate control despite treatment with metformin and/or sulfonylureas [1]. - The company has invested approximately RMB 44.1834 million in the research and development of this project [2]. Group 2: Industry Context - Semaglutide is a long-acting GLP-1 receptor agonist that stimulates insulin production, suppresses glucagon secretion, and reduces appetite, playing a significant role in treating type 2 diabetes and aiding weight management [1]. - The original product of Semaglutide injection was developed by Novo Nordisk, which reported total revenue of USD 29.296 billion for the product in 2024 [2]. - Currently, Novo Nordisk is the only company with the Semaglutide injection product approved for market in China [1].

Market Performance - The pharmaceutical sector experienced a decline of -1.91% on September 9, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 28th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, pharmaceutical distribution (-0.52%), blood products (-0.62%), and in vitro diagnostics (-0.73%) performed relatively better, while medical R&D outsourcing (-3.63%), medical devices (-2.47%), and medical consumables (-2.06%) lagged behind [1] - Top three gainers included Rongchang Bio (+11.92%), Hehua Co. (+10.07%), and Zhend Medical (+10.00%), while the largest decliners were Yifang Bio (-11.74%), Huahai Pharmaceutical (-10.00%), and Chenxin Pharmaceutical (-8.42%) [1] Industry News - BMS announced positive results from the Phase II clinical trial of Pumitamig, a bispecific antibody developed in collaboration with BioNTech for the treatment of extensive-stage small cell lung cancer (ES-SCLC), showing a confirmed objective response rate (cORR) of 76.3% and a disease control rate (DCR) of 100% [2] - Pumitamig targets PD-L1 and VEGF-A, designed to restore the function of effector T cells in the tumor microenvironment while locally neutralizing the effects of VEGF-A [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration for its product, Eicosapentaenoic Acid Ethyl Ester Soft Capsules, to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [3] - Taiji Group (600129) reported that its subsidiary Fuling Pharmaceutical Factory received a clinical trial approval notice for Semaglutide injection for the treatment of type 2 diabetes [3] - Huahai Pharmaceutical (600521) disclosed that its subsidiary Huahai Jiancheng underwent a pre-approval inspection by the FDA from July 14 to 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin, which met the CGMP requirements [3] - Dongfang Bio (688298) announced that its subsidiary Laihe Bio obtained a Class III medical device registration certificate for its influenza virus antigen detection kit (colloidal gold method), enhancing the company's product portfolio in the respiratory joint detection field [3]

Core Viewpoint - Taiji Group's wholly-owned subsidiary has received approval for clinical trials of Semaglutide injection from the National Medical Products Administration [1] Group 1 - Taiji Group announced on the evening of September 9 that its subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory Co., Ltd., has received the "Drug Clinical Trial Approval Notice" for Semaglutide injection [1]

Group 1 - Matrix Co., Ltd. announced that its wholly-owned subsidiary, Anke Technology, introduced a strategic investor, Shenzhen Jifu New Industry Venture Capital Fund, which invested 5 million yuan for a 10% stake [1] - Heng Rui Medicine received approval from the National Medical Products Administration for its Eicosapentaenoic Acid Ethyl Ester Soft Capsule, aimed at reducing triglyceride levels in patients with severe hypertriglyceridemia [1] - Mo Gao Co., Ltd. announced the resignation of its Vice President Jin Baoshan due to job transfer [1] Group 2 - Yao Wang Technology decided to terminate two fundraising projects and will permanently supplement the remaining funds into working capital [2] - Minhe Livestock reported sales of 25.53 million chicklings in August, generating revenue of 86.41 million yuan, with year-on-year growth of 27.60% [2] - Sichuan Jinding announced the resignation of its Director and General Manager Xiong Jifeng due to personal reasons [3] Group 3 - Taiji Group received approval for clinical trials of its Semaglutide Injection, aimed at blood sugar control in type 2 diabetes patients [5] - Jieput announced plans to increase capital in its affiliate, Suidong Intelligent Technology, with an investment of 5 million yuan for a 5% stake [7] - GeLing Deep Vision's controlling shareholders committed not to reduce their shareholdings for six months starting from September 17, 2025 [8] Group 4 - Huafeng Superfiber reported the resignation of its Vice President Liu Cong due to personal reasons [9] - Xiaoming Co., Ltd. reported sales revenue of 79.90 million yuan from chicken products in August, with year-on-year growth of 11.73% [11] - Lion Head Co., Ltd. announced that its application for issuing shares and cash to acquire assets has been accepted by the Shanghai Stock Exchange [12] Group 5 - Jinlong Automobile reported a bus sales volume of 4,074 units in August, a year-on-year increase of 23.6% [43] - Metro Design signed a contract for the Ho Chi Minh City urban rail transit project in Vietnam, with a total amount of 1.754 trillion VND [45] - North New Road and Bridge announced winning a mining construction project worth 504 million yuan [28]

Core Viewpoint - Taiji Group's subsidiary Fuling Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection for type 2 diabetes [1] Group 1: Company Developments - Fuling Pharmaceutical, a wholly-owned subsidiary of Taiji Group, has been granted a Clinical Trial Approval Notice for Semaglutide injection [1] - The clinical trials will focus on the indication of type 2 diabetes, specifically for blood sugar control in adult patients [1] - The total research and development investment in this project amounts to approximately 44.1834 million yuan [1] Group 2: Product Information - Semaglutide injection is classified as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist [1] - It is intended for use in adult patients with type 2 diabetes to manage blood sugar levels and reduce the risk of major cardiovascular adverse events in those with cardiovascular disease [1]

Core Viewpoint - Taiji Group's subsidiary has received approval for clinical trials of Semaglutide injection, indicating a significant step in diabetes treatment and weight management [1] Company Summary - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for Semaglutide injection [1] - Semaglutide is a long-acting GLP-1 receptor agonist that stimulates insulin production, suppresses glucagon secretion, and reduces appetite and food intake [1] Industry Summary - Semaglutide plays a crucial role in the treatment of type 2 diabetes and assists in weight management, highlighting its importance in the pharmaceutical industry [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-071 重庆太极实业（集团）股份有限公司 关于获得司美格鲁肽注射液药物临床试 验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 近日，重庆太极实业（集团）股份有限公司（以下简称：公司） 全资子公司太极集团重庆涪陵制药厂有限公司（以下简称：涪陵制药 厂）收到国家药品监督管理局关于司美格鲁肽注射液的《药物临床试 验批准通知书》，现将相关情况公告如下： 一、药物基本情况 药品名称：司美格鲁肽注射液 剂型：注射剂 申请事项：境内生产药品注册临床试验 本次涪陵制药厂获批临床的适应症为适用于成人 2 型糖尿病患 者的血糖控制：在饮食控制和运动基础上，接受二甲双胍和/或磺脲 类药物治疗血糖仍控制不佳的成人 2 型糖尿病患者；适用于降低伴有 1 心血管疾病的 2 型糖尿病成人患者的主要心血管不良事件（心血管死 亡、非致死性心肌梗死或非致死性卒中）风险。 截至本公告日，经查询国家药品监督管理局数据库，国内仅有原 研企业诺和诺德（Novo Nordisk In ...

Core Viewpoint - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received approval from the National Medical Products Administration for the clinical trial of Semaglutide injection for type 2 diabetes, indicating progress in the company's drug development pipeline [1] Group 1 - The clinical trial application for Semaglutide injection was accepted on July 4, 2025, and meets the requirements for drug registration [1] - The company has invested approximately RMB 44.1834 million in the research and development of this project to date [1]